UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

09 First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Read More Share:

Jan

11 Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Read More Share:

Nov

14 UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Oct

18 BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Aug

01 Evolving Expectations for Dermatological Conditions

Read More Share:

Feb

10 Partnering With the Dermatology Community to Improve Health Equity

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Oct

10 Using Data and Technology to Enable Better Patient Care

UCB has been rapidly investing in our digital business transformation to unleash the power of digital innovation to help achieve better outcomes for patients, faster.

Read More Share:

Categories

Archives

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Jan

11

Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Aug

01

Evolving Expectations for Dermatological Conditions

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Oct

10

Using Data and Technology to Enable Better Patient Care

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Jan

11

Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Aug

01

Evolving Expectations for Dermatological Conditions

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Oct

10

Using Data and Technology to Enable Better Patient Care

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact